Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
BUSINESS
Shin Nippon Biomedical Joins AnGes Vaccine Development
Japanese CRO Shin Nippon Biomedical Laboratories is the latest to join a growing list of collaborators for AnGes/Osaka University’s efforts to develop a prophylactic DNA vaccine for the novel coronavirus disease (COVID-19). SNBL, which was established in 1957 as Japan’s…
To read the full story
Related Article
- AnGes Jettisons Ancestral COVID-19 Vaccine Program
September 8, 2022
- AnGes COVID-19 Vaccine Falls Short in Clinical Trials, Focus Now on High Doses
November 8, 2021
- AnGes Launches PI/II Study for High-Dose COVID-19 Vaccine
August 18, 2021
- AnGes Adds High-Dose Trial to COVID-19 Vaccine Program
July 27, 2021
- Dosing of Low-Dose COVID-19 Vaccine Completed: AnGes PI/II Study
July 27, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
- AnGes/Osaka Univ. Plan Small COVID-19 Vaccine Study from July, Larger One from September
June 5, 2020
- Keio Univ. Spinout Weighs In on AnGes' COVID-19 Vaccine Initiatives
April 28, 2020
- Osaka Pref., Osaka Univ. Form Alliance for COVID-19 Vaccine; AnGes Clinical Study Planned as Early as July
April 16, 2020
- Peptide Institute Latest to Chip In with AnGes to Develop Novel Coronavirus Vaccine
April 15, 2020
- FunPep Joins AnGes, Osaka Univ. Partnership to Develop Novel Coronavirus Vaccine
April 9, 2020
- AnGes Now Ready to Launch Preclinical Study for Coronavirus DNA Vaccine
March 25, 2020
- Daicel, AnGes/Osaka Univ. to Collaborate in Developing COVID-19 Vaccine
March 16, 2020
- AnGes, Osaka Univ. to Pair Up to Develop DNA Vaccines for COVID-19
March 6, 2020
BUSINESS
- Pfizer Files Migraine Drug Rimegepant in Japan
November 28, 2024
- Dermatologist Hails Bimzelx as New Option for HS: UCB Seminar
November 27, 2024
- Shionogi Chided for Violating Promotion Guidelines with Actair
November 27, 2024
- Eisai, NCNP Tie Up for APOE Genetic Testing Research Sponsored by AMED
November 27, 2024
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…